Wipro helps launch new clinical drugs faster and safer, Wipro Partners with Oracle

Wipro helps launch new clinical drugs faster and safer, Wipro Partners with Oracle
Wipro Partners with Oracle to offer world class clinical solutions via Rapid Trials Platform
Bangalore, India, October 05, 2010
Wipro Technologies the global Consulting, System Integration and Outsourcing business of Wipro Limited (NYSE:WIT) today announced the launch of Wipro Rapid Trials platform to accelerate drug development across the globe.
The Wipro Rapid Trials platform is based on the Oracle Life Sciences software suite of products which is an open standards-based platform for business process integration across drug development life cycle. The platform improves data collection speed and quality by creating a cost effective and secure worldwide infrastructure (based on ISO 9001 and ISO27001 standards). This will enable organizations to conduct global trials without having to worry about IT infrastructure challenges. Wipro provides business process outsourcing services including clinical operations support and managed IT infrastructure to allow clients to achieve their clinical research and development benchmarks.

Furthermore the platform cuts the total cost of ownership by 30-40% as the resources are shared across trials while guaranteeing the highest data security possible, all without having to maintain in-house capital equipment, clinical operations.

Working with Oracle, Wipro has deployed a complete end-to-end clinical development environment which allows their clients to rapidly utilize the platform on a trial-by-trial or a specific time-based pricing model. This unique offering presents a great opportunity to small and mid-sized pharmaceutical sponsors and Contract Research Organizations (CROs) needing to standardize their clinical data collection process and operational parameters across studies and regions without having to compromise on quality. Wipro is now able to on-board new clients in as little as ten weeks with this model as against eight to twelve months earlier.

"Many enterprises find themselves challenged to deliver and standardize Electronic Data Management and Data Capture processes across their partner channels that often span multiple geographies," said  Neil de Crescenzo, Senior Vice President & General Manager, Oracle's Health Sciences Global Business Unit. "Leveraging Oracle products, like Oracle Clinical, Oracle Remote Data Capture, and Oracle Thesaurus Management System combined with its industry expertise, Wipro is very well positioned to deliver clinical trial services."

NS Bala, Senior Vice President, Manufacturing & Life Sciences Business Unit, Wipro Technologies said, "This agreement is part of our continued strategy to invest in industry based solutions, innovation and build deep industry expertise along with partners such as Oracle, Pharmasol and Icon Technical Group Inc.  The Wipro Rapid Trials solution is developed and designed to maximize the return on investment to the sponsors and provide faster time to market to help them develop drugs faster and safer". 

About Wipro
Wipro Technologies, a division of Wipro Limited (NYSE:WIT) is the first PCMM Level 5 and SEI CMM Level 5 certified global IT services organization. Wipro Technologies was recently assessed at Level 5 for CMMI V 1.2 across offshore and onsite development centers. Wipro is one of the largest product engineering and support service providers worldwide. Wipro provides comprehensive research and development services, IT solutions and services, including systems integration, information systems outsourcing, package implementation, software application management, and datacenter managed services to corporations globally.In the Indian market, Wipro is a leader in providing IT solutions and services for the corporate segment in India, offering system integration, network integration, software solutions and IT services.

Wipro also has a strong presence in niche market segments of consumer products and lighting. In the Asia-Pacific and Middle East markets, Wipro provides IT solutions and services for global corporations. Wipro's ADS' are listed on the New York Stock Exchange, and its equity shares are listed in India on the Stock Exchange - Mumbai, and the National Stock Exchange.

For more information, please visit our website at www.wipro.com
About Oracle
Oracle (NASDAQ: ORCL) is the world's most complete, open, and integrated business software and hardware systems company.  For more information about Oracle, visit http://www.oracle.com/

Oracle is a registered trademark of Oracle and/or its affiliates.

Media Contacts:

Wipro Technologies

Radhika Mahadevan
Wipro Technologies
+91- 9945042603
[email protected]
Satarupa Bhattacharya
Gutenberg Communications
+91 9886033437
[email protected]

Eric Belove
Wipro Technologies
+ 1 (732).216.6242
[email protected]

Lavanya DJ
Gutenberg Communications
+1 (212).239.8740
[email protected]

Rahul Kadavakolu
Wipro Technologies
+44 792 020 5496
[email protected]

Shalini Siromani
Gutenberg Communications
[email protected]

Forward-looking and Cautionary Statements
Certain statements in this release concerning our future growth prospects are forward-looking statements, which involve a number of risks, and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in our earnings, revenue and profits, our ability to generate and manage growth, intense competition in IT services, our ability to maintain our cost advantage, wage increases in India, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, restrictions on immigration, our ability to manage our international operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks, our ability to successfully complete and integrate potential acquisitions, liability for damages on our service contracts, the success of the companies in which we make strategic investments, withdrawal of fiscal governmental incentives, political instability, war, legal restrictions on raising capital or acquiring companies outside India, unauthorized use of our intellectual property, and general economic conditions affecting our business and industry. Additional risks that could affect our future operating results are more fully described in our filings with the United States Securities and Exchange Commission. These filings are available at http://www.sec.gov/. We may, from time to time, make additional written and oral forward-looking statements, including statements contained in the company's filings with the Securities and Exchange Commission and our reports to shareholders. We do not undertake to update any forward-looking statement that may be made from time to time by us or on our behalf.


Suggested Articles

Data from a 10,000-patient trial showed that people with osteoarthritis taking Novartis' Ilaris had 40% to 47% lower rates of joint replacements.

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.